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INTRODUCTION 
We will begin with a brief summary of our previously reported experience with 
clinical xenotransplantation (Starzl et aL 1964a, 1969b, 1989c, 1993d, 1994e). 
However, the purpose of the exercise is to delineate the fundamental issues that 
must be resolved before such procedures can be tried again, and to identify strat-
egies that may bring this objective within reach, as well as those which are apt to 
be futile. 
The choice of models for research in xenotransp1antation predetermines the 
mechanisms of xenograft destruction. With one kind of species combination (for 
example, rat- or human-to-mouse; wolf-to-dog; sheep-to-goat; subhuman pri-
mate-to-human), transplanted tissues or whole organs are subject to cellular rejec-
tion after a delay of several days in much the same way as allografts, but with a 
more prominent humoral component. With the contrasting "forbidden" combi-
nations (i.e. guinea pig-to-rat, pig-to-dog, or pig-to-human), organs are hyper-
acutely rejected by a process that is usually associated with preformed xenospec-
ific antigraft antibodies. 
The common assumption that the two kinds of outcome mirror unrelated path-
ways has added to the mystique of xenotransplantation. This misconception has 
been perpetuated by terminologies such as "concordant versus discordant" (CaI-
ne 1970) that have several indefensible implications, as discussed recently by 
Makowka & Cramer (1994) and Leventhal & Matas (1994): exclusivity of the two 
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mechanisms, a determinant role of phylogenetic distance, and uniqueness of the 
xenospecific humoral reaction relative to that seen with allografts. Recent "dis-
coveries" about the events of humoral xenograft rejection have tended to reinforce 
these stereo typic conclusions, while largely ignoring an earlier literature leading 
to the quite different conclusion that xenograft rejection, including the hyperacute 
variety, is merely an extreme expression of mechanisms that also can afflict allo-
grafts (Starzl et al. 1968, 1970). 
BABOON-TO-HUMAN XENOTRANSPLANTATION 
It was the perception of a similarity to allotransplantation that prompted the 
baboon-to-human renal xenotransplantation trials at the University of Colorado 
in 1963 before extensive research in whole organ xenotransplantation had been 
done (Starzl et al. 1964a). The only known examples of hyperacute allograft rejec-
tion had been in recipients of ABO-mismatched kidneys (Starzl et aL I 964f, 
1964g), causing us to underestimate the potential risk of immediate graft loss. 
Twenty-nine years later, the fact that the baboon kidney xenografts had not hyper-
acutely rejected, plus the availability of vastly improved immunosuppression, 
prompted a trial of baboon liver transplantation for dying patients who were 
disqualified by medical criteria for hepatic allotransplant candidacy. 
The kidney trials (1963-1964) 
The 6 patients given baboon kidneys in late 1963 and January 1964 underwent 
simultaneous bilateral nephrectomy and splenectomy, and were treated postopera-
tively with azathioprine and prednisone. Earlier in that year, Reemtsma et al. 
(1964) had paved the way with encouraging results using chimpanzee kidney 
xenografts, one of which functioned for 9 months. Although a handful of chim-
panzee xenografts were used subsequently (Cortesini et aL 1970), including a 
heart (Hardy et al. 1964) and 3 livers (Starzl et al. 1969b, 1989c), social opposition 
to using such an anthropomorphic and endI~~pecies already had served 
notice that extensive further trials would be unacceptable. We then learned from 
Dr. Claude Hitchcock of Minneapolis that he had secretly performed a similar 
operation even before Reemtsma's first case, using a baboon kidney which had 
not been hyperacutely rejected. As reported later by Hitchcock et al. (1964), this 
first xenograft of modern times was lost at 4 days from an arterial thrombosis 
which was suspected to have a technical etiology. 
Confirming Hitchcock's observation that baboon kidneys escaped hyperacute 
rejection, the 6 Colorado xenografts functioned for 6 to 60 days (Starzl et aL 
1964a, 1989c). At the end, they developed fierce cellular rejection (Porter 1964). 
However, the key histopathologic finding was occlusive endothelia litis of the graft 
vessels that had choked off much of the arterial supply. The consequent distal 
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ischemia explained a patchy gangrene of the xenografts, interspersed between 
islands of still functioning parenchyma (Porter 1964). The extensive arterial 
lesions were similar to but more acute than those previously reported in allografts 
by Porter (1963). The same kinds of gross and histopathologic findings were re-
ported more than 20 years later by Bailey et al. (1985) after baboon cardiac 
xenotransplantation under a cyclosporine-based immunosuppressive regimen (the 
Baby Fae case). 
Recipient titers of preexisting anti-donor leukocyte agglutinins declined irregu-
larly throughout the residence of the xenografts in these recipients (Starzl et a!. 
1964a, Kirkpatrick & Wilson 1964). Three of the 6 patients received ABO-mis-
matched kidneys and fared no worse than the others. The changes of the pre-
existing ABO isoagglutinin titers in all patients were random. This was not sur-
prising because ABO antigens are weakly expressed in baboon tissues and red 
blood cells. 
The conclusion from this experience was that xenospecific humoral rejection 
had been responsible for the failures (Starzl et a1. 1964a, Porter 1964, Kirkpa-
trick & Wilson 1964, Starzl 1964h). Because the futility of proceeding without an 
effective means of antibody control was obvious, a moratorium on further trials 
was self-imposed that lasted for 29 years. 
The liver trials 
The patients - In June 1992, and January 1993,2 patients with end-stage chronic 
active hepatitis caused by B virus (HBV) had their livers replaced with baboon 
organs, with survival of 70 and 26 days (Starzl et a1. 1993d, 1994e). The conven-
tionallymphocytotoxic crossmatch of the recipient sera with their donor lympho-
cytes was positive initially but negative after dithiothreitol (DTT) treatment, indi-
cating that the antibodies were predominantly IgM (Starzl et a1. 1993d, I 994e). 
Postoperatively, even the unaltered crossmatches became negative. Both patients 
had donors of their own blood type, A to A in Case I and B to B in Case 2. The 
recipients were immune-competent preoperatively with in vitro testing, although 
Patient 1 had symptomatic HIV infection, and had undergone post-traumatic 
splenectomy 3 years previously. This patient was half the age (35 years) of Patient 
2 and far less frail, still semi-conscious, and not yet on ventilator support. Patient 
2 underwent splenectomy 4 days post-transplanta.tion. 
Immunosuppression - Treatment was with FK 506, prednisone, cyclophos-
phamide, and prostaglandin E[ (PGE[). There were specific reasons for the ad-
dition of 2 drugs to the conventional FK 506-prednisone combination originally 
developed for allografts. Prostaglandin E[ (PGE 1) in combination with high in-
duction doses of prednisone had been shown not only to eliminate most of the 
risk to liver allografts posed by a positive lymphocytotoxic crossmatch (Takaya 
---- .... _ .. _ .. _ .. _ .... 
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et al. 1992a) but also to reduce the acute risk of FK 506 nephrotoxicity (Takaya 
et al. 1992a, 1993). These properties have made PGE1 a routine constituent of our 
present-day 3-drug immunosuppressive c?cktail for all liver allograft recipients. 
Although PGs are inherently but only weakly immunosuppressive (Strom & 
Carpenter 1983, Quagliata et al. 1972), they have been reported to mitigate hu-
moral rejection by tempering the cytokine-mediated inflammatory response 
(Shaw 1985, Rapaport & Dodge 1982) after hamster-to-rat (Shaw 1985, Kakita 
et al. 1975a), cat-to-dog (Mundy 1980), and pig-to-dog (Makowka et al. 1987) 
xenotransplantation. 
The 4th drug, cyclophosphamide, is one of several agents that inhibit DNA 
synthesis, suppress antibody responses by preventing B-cell clonal expansion, and 
prolong the survival in rats of hamster xenografts (Hasan et al. 1992, Murase et 
al. 1993). It was chosen in preference to several other agents with the same general 
"antiproliferative" mechanism (Murase et al. 1993) because it was an accepted 
drug in the formulary, and had been substituted for azathioprine as a conven-
tional immunosuppressant for allotransplantation in the era preceding cyclospor-
ine (Starzl et al. 1971). 
Causes of failure - There was no evidence postoperatively of recurrent HBV infec-
tion, nor any overt histopathologic findings of cellular rejection in mUltiple liver 
biopsies and at autopsy. Infectious complications were the immediate causes of 
death: ruptured mycotic intracerebral aneurysm caused by aspergillus in Case 1, 
and peritonitis secondary to a leak at the Roux-y biliary reconstruction in Case 
2. However, the underlying cause of death in both cases was SUboptimal xenograft 
function which was not satisfactorily explained at the time. In retrospect (see 
later), it was evident that the cause had been a slow-motion form of humoral 
rejection. 
The patient, who lived for 70 days, was jaundice-free for most of his survival. 
However, his serum alkaline phosphatase became elevated from the 2nd week 
onward, suggesting partial biliary obstruction. At autopsy, the entire biliary tree 
was filled with inspissated bile, and most of the biliary ducts, which had become 
bile lakes, were denuded of epithelium. The 2nd patient never woke from his 
preexisting coma, and never cleared bilirubin. At autopsy, his xenograft also was 
filled with inspissated bile. 
The manifold physiologic manifestations of hepatic dysfunction included the 
inability of either xenograft to maintain a postoperative serum albumin above 2 
g%. Both patients developed renal failure which may have had a component of 
the hepatorenal syndrome. The tendency to ascribe the postoperative graft dys-
function to rejection resulted in overimmunosuppression. The dichotomy of re-
sponse in which cellular immunity was essentially eliminated but with inadequate 
control of humoral immunity (Starzl et al. 1993d, 1994e) is the core dilemma of 
xenotransplantation. 
. . 
· . 
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The 3D-year period bracketed by the baboon kidney xenotransplantations at 
one end and the liver trials at the other was almost contemporaneous with the 
modern era of transplantation. We will attempt to show here that all of the 
advances made in between in allotransplantation, and more significantly the 
failure to achieve some objectives, are directly applicable to xenotransplanta-
tion. To illustrate the point, we will ask and attempt to answer a series of spe-
cific questions. 
DOES XENOTRANSPLANTATION POSE UNIQUE TECHNICAL PROBLEMS? 
None of the 6 kidney xenografts failed because of technical complications. How-
ever, the occurrence of lethal biliary tract problems in both baboon xenograft 
recipients mandated a close review of the operative procedures. Although the 
techniques, which were adapted from hepatic allotransplantation (Starzl et al. 
1993d, 1994e), seemed satisfactory, the body weights of the baboon donors were 
only 40% of those of the recipients, necessitating the so-called piggyback oper-
ation which leaves the recipient vena cava intact. The livers regenerated up to 
optimal volume for recipient size in both cases. The biopsies had the typical 
findings of regeneration, with multitudes of proliferating hepatocytes and duct 
cells, with almost no infiltrating immunocytes. 
Shiraishi et al. (1994) have reported that the use of small to large liver allografts 
(and by inference xenografts) introduces an increased antigenicity factor. In Shira-
ishi's experiments, the increased MHC Class II expression that is independently 
associated with liver regeneration (Jonjic et al. 1987) appeared to be responsible 
for more severe cellular and humoral rejections than seen with size-matched liver 
transplantation in the same rat strains. (Shiraishi et al. 1994). 
However, this adverse factor was not thought to be great enough to account 
for the dysfunction of the xenografts, particularly because it could be easily over-
ridden with a brief course of immunosuppression (Starz! et al. 1 994i). 
DO XENOGRAFTS IMPOSE METABOLIC INCOMPATIBILITIES? 
Having the same cholestatic problem twice without clear evidence of mechanical 
obstruction raised the possibility that the baboon liver produced a lithogenic bile 
in the human environment. The global dysfunction of the hepatic xenografts mili-
tated against such a specific non-surgical explanation. However, the more generic 
question of metabolic incompatibility has not been laid to rest. After hepatic 
replacement, liver allografts continue to produce donor-phenotype proteins and 
other synthetic products, allowing hepatic replacement to be used to correct nu-
merous liver-based inborn errors of metabolism (Starzl et al. 1989j). Because the 
same retention of donor specificity occurs after successful xenotransplantation 
(Starzl et al. 1993d, 1994e, 1993k, Valdivia et al. 1993a), the consequence of suc-
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cessfully engrafting a liver xenograft could be equivalent to transplanting an in-
born error of metabolism. That this can occur with allografts has been demon-
strated by the accidental transplantation of a coagulation disorder (Dzik et al. 
1987) and by the evidence that cholesterol patterns change to those of the donor 
following liver replacement (Kraft et al. 1989). 
During the survival of the 2 human liver recipients, metabolic "baboonization" 
included albumin, C3 complement component, properdin, and other moieties in-
volved either in classical metabolic processes, immune reactions, or blood coagu-
lation (Starzl et al. 1993d, 1993k). The fall of the patient's serum uric acid post-
operatively to the nearly undetectable level that is normal for the baboon was a 
particularly dramatic demonstration of the creation by the hepatic xenograft of 
its own chemical environment (Starzl 1993k). Although no specific harm could 
be identified from these changes, both patients required unusual quantities of red 
cell and platelet infusions postoperatively which were suspected (but not proven) 
to represent GvH reactions caused by antibodies elaborated from the dissemi-
nated baboon nonparenchymal cells (NPCs) (see later). 
The most complete metabolic studies after liver transplantation (Valdivia et al. 
1993a) have been in the hamster-Hat rodent interspecies combination in which 
the phylogenetic distance by paleontolologic and genetic evidence has been esti-
mated at 15 to 40 million years (Harten berger et al. 1985). In this model, the 
donor/recipient clotting tests are disparate, the most striking difference being that 
Protein C which is plentiful in normal hamsters is undetectable in rats. The co-
agulation profile of the rat recipients of orthotopic hamster livers quickly was 
hamsterized, without adverse consequences of bleeding or clotting (Valdivia d al. 
1993a). The change to donor-specific products of hepatic synthesis of albumin 
and other moieties also appeared to be compatible with healthy survival. 
However, the clinical signs of donor-determined metabolic aberrations may 
require years for development. After Rhesus monkey to baboon transplantation, 
Gridelli et al. (1993) have reported a B12 deficiency which, although correctable, 
was postulated to have a metabolic basis. If there are serious metabolic conse-
quences of using disparate species donors, xenotransplantation will be limited to 
organs such as the kidney and heart with less complex functions. In addition, 
alien complement synthesized by the hepatocytes and the antihost antibodies pro-
duced by the NPCs of all organs have immunologic consequences (Ramsey et al. 
1984). 
IS XENOGRAFT ACCEPTANCE ASSOCIATED WITH CHIMERISM? 
A characteristic cycle of crisis and recovery was defined 30 years ago in human 
renal allograft recipients in which the successive events were rejection, its reversal 
with intensified treatment, and the later ability to wean immunosuppression 
(Starzl et al. 1963). When studied 3 decades later, a cohort of these original 
.' 
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patients who still bore their original allografts were demonstrated to have ubiqui-
tous low level donor leukocyte chimerism (Starzl et al. 19921, 1993m). With this 
discovery and its confirmation in recipients of other kinds of organs (most promi-
nently the liver) (Starzl et a1. 1993n, 19920, 1993p, 1993q), the events following 
transplantation could be reconstructed in terms of a bi-directional cell traffic and 
a reciprocal immune transaction between the graft and host (Demetris et al. 1993, 
Qian et al. 1994). These consisted of a graft-versus-host reaction in addition to the 
conventional host-versus-graft (rejection) response (Starzl et al. 1992, Demetris et 
al. 1994) - each eventually cancelling the effect of the other in successful cases. 
The result was that the graft as well as the recipient became genetic composites. 
Because the emigrant donor cells ("passenger leukocytes") from the graft were 
multilineage and derived originally from the bone marrow, the organ transplan-
tation was in effect a mini-bone marrow transplantation. We now are supple-
menting these cells in unconditioned organ allograft recipients by giving them 
unaltered donor bone marrow at the time of organ transplantation. Postoperative 
treatment is with conventional immunosuppression. All of these allograft recipi-
ents (n=36) are well and all have chimerism, which is lOOO-fold or greater than 
that which occurs spontaneously (Fontes et al. 1994a). Eventually, drug weaning 
and discontinuance is planned. 
Striking microchimerism was demonstrated throughout life and at autopsy in 
both of our baboon liver recipients (Starzl et al. 1993d, 1994e). The first recipient, 
whose survival was 70 days, was given only a liver. Thus, the baboon DNA found 
by peR in all tissues retrieved at autopsy represented donor leukocytes that had 
migrated from the liver. Patient 2, who had been infused with 3X 108/kg baboon 
bone marrow cells after the liver xenograft was revascularized had similar mixed 
xenogeneic chimerism until death.' 
If xenotransplantation is to be successful, it seems evident that the persistence 
of the double cell population is both inevitable and obligatory (Fig. I). In chron-
ically surviving rat recipients of hamster hearts and even more dramatically in 
those given liver xenografts, chimerism was regularly seen within the grafts (Valdi-
via et al. 1993b) and systemically (Valdivia et al. 1993c). The discontinuance of 
immunosuppression after 100 days in these animals was followed by weeks or 
months of survival without further treatment before the slow onset of rejection 
(Valdivia et al. 1993b). 
There are still vast gaps in this new paradigm of graft acceptance, but some 
large ones already have been filled by chimerism studies in the mouse (Lu et al. 
1994). These have shown how potentially tolerogenic precursor dendritic cells and 
possibly other components of the multilineage migratory cells may perpetuate 
themselves after export from organ allografts. The concept of this transmutation 
in both the transplanted organ and the recipient has many potential implications 
in xenotransplantation. By knowing how graft acceptance occurs, the possibility 
has been opened of mimicking the circumstances for its accomplishment. 
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Figure 1. The double cell leukocyte population in the transplanted whole organ as well as 
the recipient which is an obligatory condition for acceptance of either allografts or xeno-
grafts. This recently defined paradigm (Starz!. et a!. 1992, 1993a, 1993b) provides a basis 
for innovative therapeutic strategies of xenotransplantation. 
DOES "HEPATIC TOLEROGENICITY" APPLY TO XENOGRAFTS? 
Cellular immunity 
The immunologic advantages of hepatic allografts and xenografts include a 
greater ease of inducing their acceptance with a limited course of immunosuppres-
sion (Starzl et al. 1965, 1969s, Murase et al. 1990a, Valdivia et al. 1991) or, in 
some swine (Garnier et al. 1965, Peacock & Terblanche 1967, Caine et al. 1967) 
or rat (Zimmerman et al. 1979, Kamada et al. 1981, Murase et al. 1990b) and 
virtually all mouse (Qian et al. 1994) strain combinations, with no treatment at 
all. Another property is the liver's unusual ability to induce a state ofimmunolog-
ic unresponsiveness to other tissues and organs of the same donor strain (Kamada 
et al. 1981, Caine et al. 1969, Valdivia et al. 1993c). We have explained these 
qualities by the heavy endowment of the liver relative to other organs (Starzl et al. 
19921, 1993n, 1993q) with potentially migratory cells of multiline age phenotypes. 
Humoral immunity 
The relative resistance of the transplanted liver to antigraft antibodies that cause 
hyperacute allograft and xenograft rejection (Kamada et al. 1981, Starzl et al. 
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1974, Houssin et al. 1985, Furuya et al. 1992), as well as the ability of the liver 
to shield other organs from humoral rejection (Fung et al. 1988, Flye et al. 1990) 
is of special interest for xenotransplantation (Valdivia et al. 1993c). The shielding 
from humoral rejections is MHC-restricted for allografts (Fung et al. 1988, Flye 
et al. 1990). However, in the hamster-Hat xenograft model the protection covers 
all third-party hamsters (Valdivia et al. 1993c), presumably because of the inbred 
nature of this species. The explanation (next section) for the liver's antibody resist-
ance is central to strategies that may allow successful clinical xenotransplantation. 
Complement 
Because the liver is the primary source of complement synthesis (Alp er et al. 
19.", Wolpl et al. 1985), allogeneic or xenogeneic liver transplantation changes 
the recipient complement system to that of the donor (Valdivia et al. 1993a, 
1993c). However, in vitro culture studies of human and rodent mononuclear 
phagocytes (CoIten 1976, Cole & Cotten 1988) showing synthesis of complement 
components means that there also are extrahepatic complement sources. Conse-
quently, the recipient's complement conversion after liver xenotransplantation to 
that of the donor species is by definition incomplete. Nevertheless, the species 
complement change has been proved by direct experimentation to be the mechan-
ism by which the hamster liver xenograft can shield all third-party hamster organs 
from humoral rejection (Valdivia et al. 1994). In these experiments, hamster 
hearts were transplanted into stable rat recipients of hamster liver xenografts. 
Then, hyperimmune antihamster sera from different species containing activated 
and inactivated complement was injected intravenously (Valdivia et al. 1994). The 
results are summarized in Figs. 2 and 3. 
In essence, the introduction of the active rat complement contained in hyperim-
mune antihamster rat serum caused prompt hyperacute rejection within a few 
minutes of a secondarily eng rafted hamster heart that otherwise would have been 
accepted under the protective umbrella of the previously engrafted hamster liver, 
and also caused rejection of the liver itself within a few hours. These lethal events 
were completely prevented by the simple expedient of decomplementing the serum 
by heating at 56°C for 30 min. This demonstration of the species specificity and 
efficacy of the complement system was confirmed by transplanting other species 
organs and by injecting other species antisera. The results were congruent with 
exhaustive in vitro assays including complement-dependent cytotoxicity (Valdivia 
et al. 1994). 
I t remains to be determined in genetically controlled models if the trans-species 
protection from humoral rejection (as well as from cellular rejection) endowed by 
the new complement environment in the hamster--Hat model has no MHC restric-
tion or, more likely, if these findings reflect the intensive inbreeding and minimal 
genetic diversity in the hamster, as we have suggested (Valdivia et al. 1993c). 
I" 
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Figure 2. Demonstration by Valdivia et aL (1994) that the complement environment of a 
xenograft recipient becomes that of the donor species. In these experiments, the dominant 
complement of rat recipients of hamster livers become hamster-specific within a few days, 
a change that was permanent. See text for further explanation. 
Figure 3. Second stage experiments of Valdivia et al. (1994) fol/owing the engraftment shown 
in Fig. 2, showing species restriction of complement activation. Rats bearing long-surviving 
hamster livers hyperacutely rejected these xenografts when injected with rat-hamster serum, 
but not if the serum was first decomplemented by heating. 
I 
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MHC restriction of complement in the context of hyperacute allograft rejection 
has been reported by Fung et al. (1988) and in more detail by Flye et al. (1990) 
in a clinical allograft setting. They showed that hypersensitized patients given 
liver allografts could then receive kidneys without the expected complication of 
humoral renal rejection. What must be accomplished for survival of either a liver 
allograft or xenograft (or organs to which they extend protection) is survival and 
function of the new liver long enough to allow the complement transition to 
begin. "Self rescue" by this means is lost too quickly in difficult xenograft models 
for this to occur. 
These findings plus the concept of chimerism as the mechanism of graft accept-
ance have suggested strategies for xenograft organ preparation that may avoid 
complement activation (see final section of this article). 
CAN XENOGRAFT CELLULAR REJECTION BE CONTROLLED? 
Although the hepatic tolerogenicity factor may have been contributory, the im-
proved immunosuppression of 1993 compared to that used in 1963 was thought 
to be the principal explanation for the virtual freedom of the hepatic baboon 
xenografts from the severe cellular rejection that was seen in earlier renal and 
cardiac cases. However, there is very limited information about what might be 
accomplished with species combinations in which the organs are hyperacutely 
rejected before drugs such as cyclosporine and FK 506 can act. This "experimen-
tal artefact" which precludes direct study of cellular rejection is not different from 
the plight of the hypersensitized human recipient for whom the provision of T-
cell directed immunosuppression is a hollow gesture. 
The magnitude of this barrier in xenograft models correlates less well with 
phylogenetic distance than with the preexisting antigraft antibody status. For ex-
ample, successful protection of skin xenografts from humans and other species 
transplanted to the distantly related mouse has been reported with ALS (Lance & 
Medawar 1968) or even without treatment (Steinmuller 1970). The unusual ease 
of xenotransplantation to mice from several species can be explained more easily 
by this animal's well-known low complement activity against these species (Gorer 
1958, Haensch et al. 1981) than by the distance of the donor on the evolutionary 
scale. 
It is particularly noteworthy that xenogeneic cells can be engrafted more easily 
than complex tissues and organs (Hullett et al. 1987, Ricordi et at 1987, Faiqui 
et al. 1991, Michejda et al. 1992, Srour et al. 1993). This has been illustrated by 
a recently reported experiment (Fontes et al. 1994b) in which 2 baboons precon-
ditioned with 7.5 Gy total lymphoid irradiation were given 6x108!kg unaltered 
human bone marrow cells, and provided with no subsequent treatment. There 
was peR evidence of human DNA in the blood of 1 animal for more than 6 
months, and permanently in the other. GvHD did not occur in either. Yet, when 
224 STARZL ET AL. 
the baboons were sacrificed at 18 months, donor DNA was found widely distrib-
uted in the tissues of both animals. In their bone marrow, colonies of burst-
forming-unit erythroid (BFU-E), granulocyte (CFU-GM), and macrophage, and 
mega-karyocytes (CFU-GEMM) tested positive by PCR for donor human DNA. 
This evidence of extensive engraftment was confirmed by the identification of 
human cells in the liver and other tissues by staining with human-specific mono-
clonal antibodies (Fontes et al. 1994b). 
In a more extreme well-documented example, xenoengraftment of porcine beta 
cells in humans was the only apparent explanation for the detection of C-peptide 
many months after the infusion of pig pancreatic islets into diabetic patients 
(Korsgren et al. 1992). This outcome contrasted with the hyperacute rejection by 
humans of pig hearts within a few minutes (Czaplicki et al. 1992) and oflivers within 
a few hours (Eiseman 1966, Norman et al. 1966, Abouna et al. 1970, Makowka et 
al. 1993). The reason for the difference with cells versus organs appears to be that 
the prime target of xenograft rejection is the vascular system. Thus, a more mean-
ingful assessment of cellular xenogenicity and the ability to control it undoubtedly 
is obtained from cell transplantation studies, and perhaps most discriminately with 
in vitro analysis. 
In vitro studies have been done, but almost no one has been willing to accept 
the results at face value. For example, AuchincJoss (1994), who demonstrated 
multiple defects in mouse T-cell response to primate stimulators (Moses et al. 
1989), has suggested that there may be alternative undefined cellular mechanisms 
(such as NK cells). The instinctive reluctance to believe that cellular rejection of 
disparate xenografts is actually less vigorous than of allografts could be dimin-
ished (although not eliminated) by bone marrow xenotransplantation experiments 
in which the occurrence of GvHD is generally conceded to be dependent on T-
cell reactivity. 
Aside from the human~baboon experiments cited above, information about 
the consequences of bone marrow xenotransplantation in so-called concordant 
species combinations has been almost exclusively from rat~mouse or mouse-Hat 
models. However, GvHD has now been produced in rats given hamster bone 
marrow following conditioning with 9.5 and 10.5 Gy total body irradiation (Pat-
ijn et al. 1994). These experiments proved the competence of xenogeneic T-cell 
reactions, but the vastly more interesting observation was the ease with which the 
GvHD could be controlled with FK 506 (unpublished data, Luis Valdivia). 
Further information is badly needed about GvHD after engraftment (if this 
proves to be possible) with more difficult combinations and especially those in 
which -~rong antibody barriers preclude survival of whole organs for more than 
a few .nutes. The critical question is if xenogeneic bone marrow from a disparate 
spec can be engrafted and proliferate in the recipient without producing GvHD 
or' h GvHD that can be readily controlled. Intriguing evidence that this might 
actually be possible was summarized by Simonsen (1962), but not pursued be-
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cause the objective of the experiments was to study GvHD, not to develop models 
of engraftment in which the experimental end points were invisible. 
Aside from their intrinsic interest. the bone marrow experiments of Patijn et 
al. (1994) have allowed more complete interpretation of the previous research on 
hamster ..... Hat whole organ transplantation. The value of this species combination 
for xenotransplant experimentation was first reported for hearts by Barker & 
Billingham (1971) and Kakita et al. (1975b) and extended subsequently to ortho-
topic liver (Murase et al. 1993, Valdivia et al. 1987, Yamaguchi et al. 1990) and 
kidney models (Miyazawa et al. submitted). The events and mechanisms of ham-
ster heart, kidney, and liver rejection in rat recipients have been extensively de-
scribed (Valdivia et al. 1987, Yamaguchi et al. 1990, Miyazawa et al. submitted, 
Knechtle et al. 1987a, Monden et al. 1989, Van Den Bogaerde et al. 1991, Cramer 
et al. 1992, Langer et al. 1993) with emphasis on the preformed low level hamster-
specific xenoantibodies. These antibodies have been demonstrated with in vitro 
cytotoxic assays using hamster lymphocytes or endothelial cells as targets and 
with an indirect immunofluorescence assay showing xenospecific immunoglobulin 
binding to tissues. Despite the ominous presence of these antibodies, hyperacute 
rejection of the heart, kidney, and liver does not occur. However, rapid B-cell 
activation and xenospecific antibody production causes pure humoral rejection of 
the heart and kidney in 3 days. The liver with its well-known resistance to anti-
body rejection (Murase et al. 1993, Valdivia et al. 1991) is destroyed in 7 days by 
a combination of humoral and cellular rejection. 
The duality of the immune response, with a strong but briefly delayed antibody 
component, makes it easy to understand why the most potent T-cell directed 
agents, cyclosporine and FK 506, do not prolong the survival of hamster kidneys 
or hearts when used alone to treat the rat recipients, but become effective when 
they are combined with a long list of agents (or with splenectomy) that suppress 
the antibody response (Hasan et al. 1992, Murase et al. 1993, Valdivia et al. 1987, 
Yamaguchi et al. 1990, Miyazawa et al. submitted, Knechtle et al. 1987a, Monden 
et al. 1989, Van Den Bogaerde et al. 1991, Cramer et al. 1992, Langer et al. 
1993). Murase et al. (1993), who provided the most complete studies of this kind, 
summarized by saying "by breaking down the antibody barrier ... it has been possible 
with FK 506 to transplant hearts and livers in the moderately difficult hamster to 
rat xenotransplantation model as easily as in many allogeneic strain combinations 
and more easily than in some". The list of these "adjuvant" drugs has become too 
long to review here but some which also have potent anti-T cell activity have been 
touted as primary drugs for xenotransplantation. The greatest claims have been 
for leflunomide (Xioa et al. 1994, Kemp et al. in press) and Brequinar (Makow-
ka & Cramer 1994, Cramer et al. 1992). 
Although these drugs all prolong xenograft survival, the rate of immunolog-
ically mediated complications of the xenografts of survivors is high despite pro-
vision of chronic T-cell directed immunosuppression. This has been particularly 
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well illustrated by the high rate of late bile duct and ureteral problems in liver 
and kidney xenografts. These organs usually have histopathologic evidence of 
inflammatory reactions but contain few or no lymphocytes. We believe that the 
abnormalities reflect ongoing humoral more than uncontrolled cellular rejection. 
CAN HUMORAL REJECTION BE CONTROLLED'? 
This brings us squarely to humoral rejection, the central issue of xenotransplanta-
tion, and also the principal unresolved problem of allotransplantation. Because 
humoral rejection, whether of allografts or xenografts, has been the cui de sac of 
transplantation immunology for more than 30 years, it is important to have a 
precise idea of how our understanding of this complication evolved. 
What does the term mean? 
With ABO incompatibility - Hyperacute rejection was first observed more than 
30 years ago when ABO-mismatched renal allografts were transplanted into pa-
tients who had preformed antigraft ABO isoagglutinins (Starzl et al. 1 964f, 
1964g). After the kidneys were lost on the operating table, arteriograms of the 
infarcted organs showed nonfilling of the small vessels, which correlated histo-
pathologically with widespread thrombotic occlusion of the microvasculature. 
The conclusion was that the disasters had been caused by high-affinity isoaggluti-
nins in the recipient sera, which had bound with A or B antigens in the graft 
vessels and parenchymal cells. This conclusion was supported by rapid changes 
in recipient isoagglutinin titers, as well as by the previous documentation by Szul-
man (1960) and by Hogman (1959) that the ABO antigens were widely distributed 
throughout human tissues and organs. The guidelines formulated from this ex-
perience (Starzl et al. 1964f, 1964g) were designed to avoid such antibody con-
frontations (Table I). The ABO rules also apply to heart 
Starzl et al. 1987), liver (Starzl et al. 1987, Gordon et al. 1986, Demetris et al. 
1988), and other kinds of organ transplantation. 
However, not all ABO-mismatched organs met the same fate, and in fact the 
longest continuously functioning renal allograft in the world (Starzl et al. 1990) 
is a B+ kidney donated to a 38-year-old A + male recipient by his younger sister 
on January 31, 1963. This variability of response was explained by Rapaport et 
al (1968) in one of his classical histocompatibility studies in which human volun-
teers were sensitized with purified A and B antigens. This caused increased titers 
of isoagglutinin. Accelerated or hyperacute (white graft) rejection of subsequently 
transplanted ABO-incompatible skin grafts completed the circle of evidence indi-
cating the antibodies which in high titers presented an obstacle no less formidable 
than in the most severe xenograft models. However, it eventually was realized that 
the hyperacute rejection was only associated with, not dependent on, the anti-
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TABLE I 
o to non-O* 
Rh- to Rh+ 
Rh+ to Rh-
A to non-A 
B to non-B 
AB to non-AB 
Safe 
Safe 
Relatively safe 
Dangerous 
Dangerous 
Dangerous 
*0 is universal donor, AB is universal recipient. However, in cases of ABO-compatible but 
not identical transplantation El~AI B, or AB; A~AB; B~ABFI this reverse violation of 
the ABO barrier is safe for the graft but it can subject the recipient to mirror-image compli-
cations in which donor immunocytes elaborate antibodies directed against the host. These 
usually are manifested by hemolytic or thrombocytopenic syndromes. This "humoral 
GvHD" in liver recipients (Ramsey et al. 1984) provided early clues to the generic paradigm 
of allograft acceptance via chimerism shown in Fig. I Starzl et al. (1992, 1993). This form 
of GvHD, of which the ABO system provided a particularly visible example, has not been 
well studied in xenotransplantation models but is certain to be important. 
bodies and that it was more accurately described as a complement activation 
syndrome (see further on). 
With non-ABO antibodies - Less than a year after the ABO disasters of 1963, the 
same outcome was reported by Terasaki et al. (1965) in a kidney recipient whose 
sera contained preformed antigraft lymphocytotoxic antibodies. The association 
of these antibodies with the hyperacute rejection led directly to the lymphocyto-
toxic crossmatch test. Terasaki's observations were promptly confirmed and ex-
tended by Kissmeyer-Nielsen et al. (1966), and others (Williams et al. 1986, Pat-
el & Terasaki 1969). It was shown in animals as well as humans that antibodies, 
clotting factors, and formed blood elements were rapidly cleared by the grafts 
(Starzl et al. 1990, Simpson et al. 1970, Giles et al. 1970, Boehmig et al. 1971). 
Local fibrinolysis from the renal vein also was a consistent finding, and in excep-
tional cases, there were systemic coagulopathies with disseminated intravascular 
coagulation (DIC) (Starzl et al. 1970, Myburgh et al. 1969). 
Additional non-HLA antibodies such as anti-vascular endothelial cell anti-
bodies also have been associated with hyperacute or accelerated rejection (Cerilli 
et al. 1985, Brasile et al. 1985). The vulnerability of extrarenal organs including 
the antibody-resistant liver to this kind of rejection was ultimately recognized 
experimentally (Knechtle et al. 1987b, Gubernatis et al. 1987, Merion & Colletti 
1990) and clinically (Takaya et al. 1992b). However, as with ABO incompatibility, 
many recipients with preformed antibodies failed to conform to expectations and 
did not reject their allografts. 
Without detectable antibodies - The cause and effect relation of preformed antigraft 
antibodies and hyperacute rejection was universally accepted by 1969 when a seam 
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developed in the dogma. This was caused by the observation of hyperacute rejection 
in a small number of carefully studied human recipients who had no detectable anti-
bodies (Starzl et al. 1968). Although the antibody-free cases were few in number 
relative to examples associated with antigraft antibodies, they necessitated redefi-
nition of hyperacute rejection as a complement activation syndrome related to the 
Arthus reaction, inverse anaphylaxis, and the generalized Swarzman reaction 
(Starzl et al. 1968, 1970). Each of these classical complement-activation syndromes, 
characterized by multiple secondary inilammatory and coagulation events, is most 
commonly initiated by interaction of antibody and antigen, but they also can be 
independent of antibodies. In the transplantation context, this was the distinction 
between the classical pathway of complement activation in which the first steps are 
antibody-dependent. versus the alternative pathway which does not require an anti-
body trigger or the participation of complement components CI. 2. and 4. 
Slow-motion hyperacute rejection - The exclusion of an allograft or xenograft 
from the circulation by hyperacute rejection is nature's life-raft. If blood flow is 
maintained to a kidney that is the cause of complement activation, clearance may 
continue of antibodies, formed blood elements (especially platelets), and clotting 
factors with an explosive systemic coagulopathy characterized by fibrinolysis 
(Starzl et al. 1968, 1970, Myburgh et al. 1969, Weber 1989). Emergency removal 
of the graft may be the only means of relieving the crisis (Starzl et al. 1970, 
Myburgh et al. 1969, Starzl et al. 1979t, 1979u). Even if this can be avoided, renal 
allografts that pass through such a storm have a degraded prognosis. Early or 
late failure was the rule in a group of hypersensitized patients whose serologically 
detectable antibodies and immunoglobulins of all classes were reduced by thoracic 
duct fistula for 30 to 56 days - a procedure that dramatically reduces humoral as 
well as cellular immune reactivity (Starzl et aI. 1979t, Gowans 1959, Machleder & 
Paulus 1978, Niblack et al. 1975). Although hyperacute rejection of the allografts 
was prevented in 2/3 of the cases, all of the organs were lost in the next few 
months to combined humoral and cellular rejection (Starzl et al. 1979t), similar 
to the late fate of hamster xenografts in rats. 
The antibody-resistant liver - Although the liver has long been known to be resis-
tant to humoral rejection (Starzl et al. 1974), it is not impregnable. The majority 
of hepatic recipients of ABO-incompatible or lymphocytotoxic crossmatch-posi-
tive livers survive, but their ultimate prognosis is significantly degraded (Takaya 
et al. 1992b). Their hepatic allografts have a high incidence of bile duct abnor-
malities including intrahepatic stricture formation and biliary sludge formation 
similar to that found in our 2 baboon xenograft recipients (Donaldson et al. 1987, 
Batts et al. 1988, Demetris et al. 1992) and in hamster-Hat xenografts. 
Such patients also have an intraoperative liability of fibrinolysis, bleeding, and 
an excessive consumption of blood products (Weber et a1. 1989). This is the liver's 
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version of a slow-motion hyperacute rejection which mayor may not spon-
taneously abate. The clinical consequences of early hepatic failure and complex 
clotting disorders have been mimicked in untreated rats (Knechtle et al. 1987b), 
swine (Merion & Colletti 1990), and Rhesus monkeys (Gubernatis et al. 1987) 
that were presensitized with donor skin grafts. Although hyperacute rejection did 
not occur, sensitization markedly reduced the mean survival - in the monkey 
experiments to 2.5 from 26 days. 
As with the kidney, humoral rejection has been documented in livers trans-
planted into antibody-free recipients. The "slow-motion" nature of the liver's hu-
moral rejection over a period of 2 or 3 days was shown in patients who received 
contemporaneous kidneys that were hyperacutely rejected within a few minutes 
(Starzl et al. 1989v). Liver patients who inexplicably reject one liver after the 
other with no apparent explanation have been seen by us and in other centers, 
causing the word-of-mouth descriptive term "liver eaters" to be applied. In such 
cases, a strong association with preexisting or perioperative endotoxemia (which 
is a classical cause of complement activation) has been noted (Yokoyama et al. 
1989). 
The baboon~human liver xenografts - Granting that humoral rejection is a com-
plement-activation syndrome of variable expression, the fate of the baboon renal 
and hepatic xenografts in our human recipients is not mysterious in retrospect. 
Because the verifying information is unavailable from the 1963 kidney experience, 
we will confine our remarks here to the 2 recent liver cases. 
Postoperatively, total complement in both patients was depleted for most of 
the critical first 2 weeks while complement components C3, 4, and 5 became 
undetectable (Starzl et al. 1993d, 1994e). During this time, circulating immune 
complexes appeared. This complement evolution was similar to that reported pre-
viously by Manez et al. (1993) in recipients of allografts transplanted across a 
positive lymphocytoxic crossmatch. After 10 days, the complement measures re-
turned toward, but never to, normal. 
The freedom from cellular rejection in the liver biopsies and at autopsy gave 
little insight into the complement storm through which both grafts had passed. 
Sludging as well as the presence of polymorphonuclear leukocytes was seen in 
the sinusoids of the xenografts immediately after reperfusion, compatible with 
the diagnosis of an aborted hyperacute rejection (Starzl et al. 1968, 1970, Williams 
et al. 1968). The hepatocytes exhibited a very fine microsteatosis on the first 
biopsies, detectable at first only in retrospect, but becoming obvious within a few 
days, particularly in Case 2. This finding has been reported within 1 or 2 hours 
postperfusion in cases of allotransplantation with inexplicable primary hepatic 
non-function (Kakizoe et al. 1990). Although the abnormality receded, the micro-
steatosis was suspected to represent an immunologically mediated sublethal injury 
that precluded long-term success. The early biopsies also showed widespread 
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binding of IgM and IgG. The IgM but not the IgG largely disappeared from the 
graft tissues in later biopsies (Starzl et al. 1993d, 1994e). 
Hyperacute xenograft rejection 
This is the most extreme example of the complement-activation syndrome. Si-
monsen began his masterful treatise on allogeneic and xenogeneic graft-versus-
host reactions by saying: "In the whole field of modern transplantation biology, 
there are few significant contributions which were not made with utter simplicity" 
(Simonsen 1962). Xenotransplantation is no exception. Nearly 30 years ago, Per-
per & Najarian (1966a, b) defined the xenograft barrier by studying the easy 
sheep~goat species combination in which preformed antigraft antibodies were 
not present (Perper & Najarian 1966b) and the difficult one ofpig~dog (Perper & 
Najarian 1966a) in which they were. However, Good and Gewurz and their associ-
ates realized that complement activation was the critical issue, whether triggered 
(classical pathway) or not (alternative pathway) by antigraft antibodies (Clark et 
al. 1966, Gerwurz et al. 1967). This central principle was even more clearly eluci-
dated by Schilling et al. (1976). 
In side-t~-side experiments done by us in collaboration with K.A. Porter (St. Ma-
ry's Hospital and Medical School, London) and the research team of Frank 1. Di-
xon (Scripps Institute, LaJolla), the hyperacute or slow-motion humoral allograft 
rejection syndromes seen in clinical practice could be duplicated with allografts in 
sensitized dogs and with pig!::;dog kidney, liver, and spleen xenografts, varying only 
in detail (Simpson et al. 1970, Giles et al. 1970, Boehmig 1971). The immunoflou-
rescence and other histopathologic end points with the allograft and xenograft 
models were indistinguishable, and were preceded by the same kind of coagulopath-
ic changes, binding of antibodies, and sequestration of formed blood elements by 
these organs. 
The valuable encyclopedia of details compiled subsequently about the variable 
antibodies or target specificities in a variety of xenograft species combinations 
(Makowka & Cramer 1994, Auchincloss 1988, Plat t et al. 1990, 1991, Weill & 
Houssin 1994, Bach et al. 1994, Dalmasso 1992) has only added to the original 
impression that the hyperacute allograft and xenograft rejection mechanisms are 
fundamentally the same. The intractability of these syndromes to intervention 
has been rediscovered over and over (reviewed in Makowka & Cramer 1994, Au-
chincloss 1988, Platt et al. 1990, Platt & Bach 1991, Weill & Houssin 1994, Bach 
et al. 1994, Dalmasso 1992). 
Frustrating recipient treatment strategies 
Methods of altering the allograft or xenograft recipient have been recycled since 
the mid 19605, usually arousing optimism at first until it was shown that difficult 
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barriers could not be crossed. 
Antibody suppression - Because xenograft rejection is not inherently antibody-
dependent, this general approach has a predictably limited place. Splenectomy, 
which is justified by the spleen's role in antibody responsiveness (Starzl 1964w) 
prolongs organ survival in several xenograft models, especially when the pro-
cedure is combined with T-cell directed immunosuppression (Murase et al. 1993, 
Valdivia et ai. 1987, Monden et al. 1989). The ability to do the same thing phar-
macologically was discussed earlier, using drug combinations that suppress hu-
moral as well as cellular immunity. However, in our baboon xenotransplantation 
cases, the use of splenectomy plus an antibody suppressive drug regimen was 
inetTective. 
Antibody depletion - Plasmapheresis was first shown by Merkel et al. (I 971) and 
Bier et al. (1970) to prolong many-fold the survival of pig kidneys in canine 
recipients. Such techniques have been used clinically to reduce isoagglutinin titers 
before allotransplantation across ABO barriers (Alexandre et al. 1991). Techno-
logic improvements such as the staphylococcal protein A adsorbent columns (By-
gren et al. 1985) have allowed greater specificity and efficiency of immunoglobulin 
removal but with ultimately limited value. The temporary transplantation of 
"forerunner organs" in preparation for the definitive graft has been described 
with various species combinations with significant but clinically inconsequential 
protection of kidney, heart, or liver xenografts (Miyazawa et al. 1990, Simpson et 
al. 1970, Giles et al. 1970, Fischel et al. 1990, Cooper et al. 1988, Tuso et al. 
1993). The same discouraging results were obtained in human recipients of kidney 
allografts (Starzl et al. 1970, Corman et al. 1973) and a chimpanzee hepatic xeno-
grafts (Giles et al. 1970). These techniques can not be expected to playa signifi-
cant role in clinical xenotransplantation. 
A reduction of humoral as well as cellular immunity can be accomplished with 
thoracic fistula in 5 days in rats (Gowans 1959) and >28 days in humans (Starzl 
et al. 1979u). However, hypersensitized humans conditioned in this way either 
rejected their kidney allografts hyperacutely or had a slow-motion version which 
in some cases was accompanied by a systemic coagulopathy and thrombocyto-
penia that necessitated graft nephrectomy (Weber et al. 1989). 
Most recently, complete removal of IgM with monoclonal antibody did not 
prevent hyperacute heart rejection in the guinea pig ..... nat model (Soares et al. 
1994). This provided evidence of alternative pathway complement activation. 
Inhibition of complement cascade - Crude snake venom (Gewurz et ai. 1967), the 
chelating agents sodium citrate (Linn et al. 1970, Kux et al. 1971), and ethylene-
diamine-tetraacetate (EDTA) (Belitsky et al. 1973) given intraarterially were 
shown more than 20 years ago to mitigate hyperacute pig~canine kidney rejec-
-------------------------------------------
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tion_ Interest in this approach lagged until better agents became available that 
allowed intervention at specific critical levels of the complement cascade: modified 
cobra venom (Van Den Bogarerde et al. 1991, Leventhal et aL 1993), soluble 
recombinant complement receptor Type I (Pruitt et al. 1994, Xia et al. 1993), and 
a sesquiterpene compound called K 76 (Starzl et al. 1994e, Miyagawa et al. 1993). 
Although all of these products dramatically improve organ survival in difficult 
xenotransplantation models, continuous infusion is required. Toxicity of the 
agents or the adverse consequences of complement depletion per se limits therapy 
to a few hours or days. When treatment is stopped, hyperacute rejection promptly 
supervenes. 
Inhibition of the inflammatory response - Used singly or together, platelet-activat-
ing factor (PAF) receptor antagonists (Makowka et al. 1987) and prostanoids 
(Mundy 1980, Makowka et al. 1987) modestly prolong the survival of pig-to-
dog and cat-to-rabbit kidney xenografts by slowing the inflammatory/coagulation 
response to complement activation. 
Alteration of the graft 
The possibility of making the organ graft a less spectacular immunologic target 
is an old idea that holds the best hope for clinical application. The first attempts 
to do this were with occupation of antibody binding sites with recipient F (ab')2 
immunoglobulin fragments. Allografts pretreated in this way and transplanted to 
hypersensitized animals (Shaipanich et al. 1971) and to an antibody-laden human 
recipient (Corman et al. 1973) resulted in little or no prolongation of survival. 
The same has been true for pretreated guinea pig hearts transplanted to rats 
(Gambits et al. 1992). 
Two recent strategies designed to alter the cell composition of the graft appear 
more logical because (as discussed earlier) this is what happens in successfully 
transplanted allografts and xenografts. 
Production of chimeric organs - The feasibility was described earlier of pre-popu-
lating baboon xenografts with a human leukocyte population and of the produc-
tion of full hamster~rat chimerism in lethally irradiated rats or hamsters whose 
GvHD could be controlled with FK 506 (Luis Valdivia, unpublished data). It 
remains to be seen if incomplete or even full chimerism will change the image of 
baboon organs enough to make them viewed as allografts by humans. 
There is evidence from pilot experiments in our laboratory that this may be a 
realistic hope (Luis Valdivia, unpublished observation), Under normal circum-
stances, mouse----Hat heterotopic heart and orthotopic liver xenografts are rejected 
by unaltered recipients in 2 and 7 days, respectively, in much the same way as 
with the comparable hamster--Hat models. However, when mouse donors were 
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first made fully chimeric with lethal total body irradiation and reconstituted for 
at least 3 months with rat bone marrow, the livers in 3 pilot experiments were 
received by rats as if they were allografts, without rejection for more than 2 weeks. 
The presence of chimerism for shorter periods (3 to 7 weeks) in the hamster-Hat 
models was without effect. 
The same experiments with guinea pig~rat combinations are in progress. It 
will be especially important to determine, first, in which combinations cross-spe-
cies donors can be produced without fatal GvHD, and second, whether this la-
borious preparation will achieve the desired purpose, particularly with disparate 
models. If this proves feasible, the preparation of pig organs for human use would 
be only one step beyond. 
Allograft and xenograft repopulation is confined to the hematolymphopoietic 
lineages, excluding parenchymal and vascular endothelial cells (Starzl et al. 19921, 
!993n, Demetris et al. 1993, Qian et al. 1994). Because the principal receptor sites 
of complement are found in leukocyte lineages (Roitt et al. 1989), these white cells 
would not be expected to initiate xenogeneic complement activation. However, 
endothelial cells also are replete with complement receptors, and whether the 
failure to replace them will be a fatal flaw in the plan will have to be determined 
by direct testing. The chance of xenoengraftment of the altered organs should be 
increased by peri operative infusion of the chimeric bone marrow of the organ 
donor in the same way as in the current donor leukocyte augmentation trials 
(Fontes et al. 1994a). 
An important organ-specific question concerns the ongoing complement pro-
duction by baboon hepatocytes of the altered hepatic xenografts. If the species 
complement restriction demonstrated by Valdivia et al. (1994) is operational (see 
earlier), this will preclude the use of hepatic xenografts. This possibility ~lso can 
be clarified by preliminary experimentation in animal-to-animal models. 
Humanization of xenografts by gene transfection - The creation of transgenic pig 
donors whose cells have pt;rmanently transfected human complement regulatory 
proteins is described elsewhere in this volume, and was the most discussed topic 
at the Second International Xenotransplantation Conference (Cambridge, Sep-
tember 26-29, 1993). Because only one of the factors that contribute to the xeno-
graft barrier is targeted by this approach, the proposed solution seems almost 
too narrowly specific to be successful. However, with the full human genome in 
sight, the prospect of creating completely humanized human organs in animals 
no longer can be dismissed as a visionary illusion. 
SUMMARY 
Recent discoveries have suggested that the exchange of multiple leukocyte lineages 
between grafts and host and subsequent long-term chimerism in both is the semi-
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nal mechanism of the acceptance of organs transplanted from the same (allo-
grafts) or different species (xenografts). This insight suggests new strategies which 
may allow xenotransplantation, the principal obstacle to which has been humoral 
rejection. We have defined humoral rejection as a family of complement activation 
syndromes afflicting allografts and xenografts in which there is a strong (but not 
invariable) association with preformed antigraft antibodies, invariable evidence 
of complement activation, histopathologic stigmas of vascular endothelial dam-
age, and a concomitant local or systemic coagulopathy. The generic descriptive 
term hyperacute rejection is a misnomer because a slow-motion version of the 
same "humoral" process can occur with some allografts and is the rule with the 
so-called concordant species xenotransplantations. The pathway of experience 
and discovery leading to this conclusion shows clearly that the distinction fre-
quently made between allograft versus xenograft humoral rejection does not actu-
ally exist in principle, but only in details and intensity. 
Breaking down this barrier to xenotransplantation, whether or not it is associ-
ated with antibodies, is unrealistic. However, the possibility of avoiding the bar-
rier has been exposed by showing that animal organs can be humanized, with a 
mixed donor and recipient cell population similar to the chimerism seen in long 
surviving allografts or even with complete leukocyte replacement. Pilot experi-
ments in rodents suggest that organs from fully xenogeneic chimeras can be made 
into xenogeneic targets that are no more provocative of complement activation 
than allografts when they are transplanted into the donor bone marrow species. 
Although the validity of this concept of organ xenograft preparation is only at 
the pilot stage of verification, there is reason to suspect that the complement 
trigger of humoral rejection can be thereby disarmed. If this can be accomplished, 
independent evidence suggests that cellular rejection can be controlled with con-
ventional T-cell directed immunosuppression, perhaps even with surprising ease. 
The potential subtle liability of synthetic products of xenogeneic parenchymal 
cells is not yet known. 
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